News >

Prexasertib Promising in BRCA Wild-Type Ovarian Cancer

Jason Harris
Published: Friday, Feb 02, 2018

cervical cancerPrexasertib (LY2606368), a cell cycle checkpoint kinase 1 and 2 inhibitor, induced a 29% response rate with acceptable tolerability in women with measurable, recurrent high-grade serous or high-grade endometrioid ovarian carcinoma.

Twenty-two (79%) patients received prophylactic granulocyte colony-stimulating factor after the first cycle to avoid treatment delays or dose reductions. Two (7%) patients had dose reductions, 1 because of recurrent grade 4 neutropenia lasting longer than 7 days during cycle 4 despite the use of filgrastim (Neupogen), and 1 because of recurrent grade 3 anemia during cycle 6 that was refractory to blood transfusion. No patients discontinued treatment because of a TEAE.
Lee J, Nair J, Zimmer A, et al. Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study. Lancet Oncol. 2018; 19:207-215. doi: 10.1016/ S1470-2045(18)30009-3.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Show Me the Data™: Leveraging Evidence to Optimize Applications of PARP Inhibitor Strategies in Ovarian CancerJun 29, 20191.5
Oncology Briefings™: Current Perspectives on Preventing and Managing Tumor Lysis SyndromeJun 30, 20191.0
Publication Bottom Border
Border Publication
x